News

Experts Recommend Against Serum PCT as Biomarker in Ph-Negative MPNs

03/29/2021

Study findings lead experts to recommend against the use of serum procalcitonin (PCT) as a disease biomarker in patients with MPNs.

Study findings lead experts to...

03/29/2021

Oncology

Conference Insider

Naveen Pemmaraju, MD, Provides an Overview of Novel Therapies for MPNs

03/01/2021

During the virtual Great Debates & Updates in Hematologic Malignancies, Dr Pemmaraju discussed new therapies for myeloproliferative neoplasms (MPNs) with a focus on CMML.

During the virtual Great Debates...

03/01/2021

Oncology

News

Azacitidine–Eprenetapopt Combo Yields Responses in Patients With TP53-Mutant MDS

01/29/2021

Study findings suggest that eprenetapopt plus azacitidine is well-tolerated and leads to high rates of response and remission in patients with TP53-mutant MDS and oligoblastic AML.

Study findings suggest that...

01/29/2021

Oncology

News

Serum Ferritin Level Tied to Fibrosis in Older Patients With MF

01/28/2021

Researchers have observed a significant link between serum ferritin level and fibrosis in older patients with MF.

Researchers have observed a...

01/28/2021

Oncology

News

Pevonedistat Added to Azacitidine Promising for Higher-Risk MDS

01/12/2021

Pevonedistat plus azacitidine yields comparable safety to azacitidine monotherapy and demonstrates improvements in OS, EFS, and response rates in patients with higher-risk MDS.

Pevonedistat plus azacitidine...

01/12/2021

Oncology

News

Guadecitabine Maintenance Therapy Shows Promise in High Risk MDS/AML Patients

01/01/2021

Guadecitabine, when given as maintenance therapy following allo-SCT, showed promising relapse-free survival rates with manageable safety in high-risk MDS/AML patients.

Guadecitabine, when given as...

01/01/2021

Oncology

News

Ruxolitinib Plus Azacitidine Tolerable for Advanced Phase MPN, Post-MPN AML

12/02/2020

Ruxolitinib combined with azacitidine was a well-tolerated therapy option for patients with advanced phase MPN and post-MPN AML.

Ruxolitinib combined with...

12/02/2020

Oncology

News

Rigosertib-Azacitidine Combo Shows Promise in Patients With MDS, AML

10/14/2020

A combo therapy regimen of rigosertib and azacitidine yielded an overall response rate of >50% in patients with MDS, CMML, and AML.

A combo therapy regimen of...

10/14/2020

Oncology

News

Second Cancers a Cause of Death for Patients With Ph-Negative MPN

09/01/2020

Study findings suggest that second cancers are a relevant cause of death opposing MPN evolution in patients with Philadelphia-negative MPN.

Study findings suggest that...

09/01/2020

Oncology

News

FDA Approves Oral Decitabine–Cedazuridine Combo for Adults With MDS

07/07/2020

The FDA has approved an oral combination of decitabine and cedazuridine for the treatment of adults with MDS.

The FDA has approved an oral...

07/07/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology